Strategic Asset Leasing, Inc.
LEAS
Other OTC0.00
USD
+0.00
- -
Strategic Asset Leasing, Inc.
LEAS
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Strategic Asset Leasing, Inc., operating under the brand ANEW Medical, Inc., is a biotechnology and medical product development company focusing on innovative therapeutics and diagnostics for life-threatening diseases. The company's core products include gene therapies targeting aging-related conditions, neurodegenerative disorders such as Alzheimer's disease, cancer, and autoimmune diseases; biosimilar biologics; and a portfolio of generic oncology drugs. Notably, ANEW Medical has acquired five market-approved anti-cancer drugs used in established chemotherapy regimens such as FOLFOX and FOLFIRI for colorectal and gastric cancers, as well as treatments for metastatic lung cancer, which it plans to market in Europe and subsequently in the U.S. The company also develops proprietary gene delivery systems centered on the Klotho protein. Recent major changes include the company's rebranding and strategic pivot towards biotechnology from its former asset leasing focus, a definitive merger agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD), and establishment of several subsidiaries including CryptoGen, LLC for cryptocurrency mining and digital asset operations. The launch of Leascoin, a new cryptocurrency on the Aspire Gas (GASP) blockchain, is intended to support future acquisitions in cryptocurrency mining and cannabis banking platforms, demonstrating diversification into FinTech and blockchain technologies. Additionally, ANEW Medical has secured new patents internationally, including through the European Patent Organization and in China, to protect its gene therapy and protein delivery technologies. Founded in 1988 and headquartered in the United States with operations extending to Spain, Strategic Asset Leasing serves global markets primarily through innovative healthcare solutions. The company targets patients suffering from complex and critical conditions, healthcare providers, and global pharmaceutical distribution channels. It operates within the biotechnology, pharmaceutical, and FinTech industry segments, emphasizing cutting-edge gene therapies, biosimilars, and digital asset services. This multifaceted approach reflects the company's evolution from asset leasing to a diversified corporate entity active in biotechnology innovation, fintech, and blockchain-driven operational assets.
ANEW MEDICAL ANNOUNCES KEY PATENT ISSUED IN CHINA TO PROTECT KLOTHO PROTEIN AND GENE DELIVERY SYSTEMS
ANEW MEDICAL, INC. to Present at the Emerging Growth Conference on Wednesday, 01/11/23